June 16, 2023


Zoetis releases 2022 Sustainability Report




Zoetis published its 2022 Sustainability Report, "Together We Are Making a Difference for a Better World", on June 15, describing the company's progress toward achieving its "Driven to Care" long-term sustainability aspirations and continued disclosure on environmental, social and governance (ESG) topics.


The report highlights the company's journey to advance sustainability in animal health for a better future through specific actions that support communities, animals and the planet. These commitments build on Zoetis' purpose and help achieve the United Nations' Sustainable Development Goals (SDGs). Included in the report is the company's ESG Index, which shares key ESG performance indicators, including those identified by the Sustainability Accounting Standards Board (SASB) for the healthcare – biotechnology and pharmaceuticals industry.


The index also includes environmental and social data as well as details on how Zoetis supports the Taskforce on Climate-related Financial Disclosure (TCFD) and its commitment to disclosing progress aligned with TCFD recommendations.


"In our third year of reporting to our Driven to Care aspirations and targets, we continue to make significant progress in our journey toward building a healthier future for our communities, animals and the planet," said Jeannette Ferran Astorga, executive vice president of corporate affairs and communications and chief sustainability officer at Zoetis, and president of the Zoetis Foundation. "The progress we've made toward our sustainability commitments would not be possible without the dedication, creativity and innovation of our colleagues who champion our purpose by contributing to a better future for us all."


Last year, Zoetis received approval for several livestock vaccines in additional markets, which support the Health for Animals Roadmap to Reducing the Need for Antibiotics. This includes recombinant vector vaccines in Brazil, India, Mexico, and the United States that can positively impact welfare and productivity of poultry, as well as expanded regulatory approval for a vaccine to help protect cattle against Mycoplasma bovis.


Additional new products support cattle producers' health and productivity goals as well as pork producers' animal welfare and productivity goals, all these to improve their sustainability.


Zoetis also announced a research collaboration with scientists in New Zealand to explore mechanisms that may inhibit methane emissions from grazing ruminants and, in turn, reduce greenhouse gas (GHG) emissions.


Furthermore, the company invested in research to support understanding how genetic testing and genomic predictions can help improve dairy cattle health outcomes by reducing disease incidence and antibiotic use while also improving productivity.


Zoetis reported progress on five years of its African Livestock Productivity and Health Advancement (ALPHA) initiative with the aim to help improve livestock health and positively impact farmers' livelihoods in Sub-Saharan Africa. At the completion of the initiative, the company trained over 30,000 farmers, veterinary professionals, distributors and lab personnel – 30% were women – and treated 9.7 million cows and 196 million chickens in the region.


With continued support from the Bill & Melinda Gates Foundation, Zoetis launched ALPHA Plus - a new five-year initiative that will scale up the initial efforts with expansion into seven additional countries in Africa and aquaculture in addition to cattle and poultry. The success of the initiative is further supported by Zoetis' inclusion in Fortune's 2022 Change the World list, underscoring the initiative's impact to grow access to veterinary care in emerging markets and to help achieve the UN SDGs for No Poverty, Zero Hunger and Gender Equality, among others.


Meanwhile, to reduce GHG emissions throughout the company's operations and manage climate risks, Zoetis set a goal in 2022 to achieve carbon neutrality in its own operations by 2030, with a focus on Scope 1 and 2 emissions from its manufacturing and R&D operations, office locations and fleet vehicles.


Aligned with its RE100 commitment, Zoetis reported 14.7% renewable electricity sourced to date and installed four photovoltaic solar arrays at three manufacturing sites and one R&D site. To date, 31% of the company's manufacturing sites operate with 100% renewable electricity. Zoetis exceeded and retired its target to reduce energy intensity by 5% at its manufacturing and R&D sites, with a 13.5% reduction.


In 2022, the company developed a roadmap to achieve its carbon neutrality target that includes short-, medium- and long-term initiatives, including capital expense planning. Specifically, it conducted energy and carbon assessments at 10 of its largest energy consuming sites, accounting for approximately 90% of the company's energy footprint, which helped identify more than 100 energy efficiency projects. Minimising fleet emissions also are part of the company's journey to carbon neutrality in its own operations, and in 2022, electric vehicles represented 1.2% of Zoetis' total fleet, while hybrids accounted for 10%.


Zoetis continued to take meaningful steps to reduce its environmental footprint and improve its products' environmental impact throughout their life cycle in markets around the world. The report highlights initiatives in Japan, Canada and the US that help streamline Zoetis' process, reduce packaging and divert packaging from landfills, including by transitioning prescription labeling to QR codes and removing cotton from product packaging.


Zoetis also created a sustainable packaging guidance document for suppliers to provide packaging specification guidelines for all products delivered to Zoetis.


- Zoetis

Video >

Follow Us